Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- AbbVie and Novartis are both top-tier global pharmaceutical companies, but they are navigating distinctly different phases of their product lifecycle journeys.
- AbbVie has successfully moved past its Humira patent cliff and is now delivering robust revenue growth driven by immunology blockbusters Skyrizi and Rinvoq.
- Novartis posted strong 2025 results with a 40.1% core operating margin, yet it faces what management calls "the largest patent expiry in its history" in 2026, primarily from Entresto.
- AbbVie offers a higher forward dividend yield and a longer track record of consecutive annual dividend increases, while Novartis has been growing its dividend at a faster pace in recent years.
- On valuation, Novartis appears comparatively undervalued based on discounted cash flow analysis, while AbbVie commands a premium that reflects its stronger near-term growth momentum.
- Both companies are actively acquiring and licensing pipeline assets, making strategic M&A (mergers and acquisitions) a central part of each growth story.
Introduction
In the global pharmaceuticals sector, ABBV (AbbVie Inc.) and NVS (Novartis AG) stand out as two of the most closely watched names by institutional and retail investors alike. Both companies operate across immunology, oncology, neuroscience, and cardiovascular medicine, yet they are at fundamentally different junctures in their strategic cycles. AbbVie has emerged from its post-Humira transition with accelerating momentum, while Novartis is bracing for a major wave of generic competition in 2026. For traders and long-term investors evaluating relative positioning in the large-cap pharmaceutical space, understanding how these two industry leaders compare across growth profiles, risk exposure, and market sentiment is essential to making informed allocation decisions.
ABBV Overview and Recent Performance
AbbVie, headquartered in North Chicago, Illinois, has established itself as a dominant force in immunology and neuroscience. The company's flagship immunology franchise — anchored by Skyrizi and Rinvoq — has more than offset the steep revenue decline from Humira, which lost U.S. patent exclusivity in early 2023. In its most recent quarterly results, AbbVie reported worldwide net revenues of $15.8 billion, an increase of 9.1% on a reported basis. Skyrizi alone generated $4.7 billion in the quarter, reflecting 46.8% year-over-year growth, while Rinvoq added $2.18 billion, up 35.3%. The neuroscience portfolio also delivered standout performance, with combined Ubrelvy and Qulipta sales rising sharply. Full-year 2025 revenue reached $61.16 billion, an all-time high.
Not all segments have thrived. The aesthetics portfolio, which includes Botox Cosmetic and Juvederm, declined roughly 3.7% in the most recent quarter as macroeconomic headwinds weighed on consumer discretionary spending. AbbVie has responded by going on an aggressive acquisition spree — completing more than 30 M&A transactions since early 2024 — including the acquisition of Capstan Therapeutics for next-generation CAR-T (chimeric antigen receptor T-cell) technology in autoimmune disease and bretisilocin from Gilgamesh Pharmaceuticals for major depressive disorder. The company recently raised its quarterly dividend by 5.5% and provided an upbeat 2026 earnings outlook, reinforcing confidence in its post-Humira growth trajectory.
NVS Overview and Recent Performance
Novartis, based in Basel, Switzerland, has transformed into a pure-play innovative medicines company following the spin-off of its Sandoz generics business in 2023. The company concentrates on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. In 2025, Novartis delivered net sales of $54.53 billion, an 8% increase at constant currencies, with core operating income rising 14% and the core operating margin reaching 40.1% — a milestone the company had originally targeted for 2027. Free cash flow reached $17.6 billion, supporting both a proposed 5.7% dividend increase and a new $10 billion share buyback program.
Key growth drivers include Kisqali, a breast cancer therapy whose sales surged 57% to $4.78 billion in 2025, and Pluvicto, a radioligand therapy for prostate cancer that generated $1.99 billion, up 42%. Scemblix, a chronic myeloid leukemia treatment, recorded 85% sales growth, and cholesterol drug Leqvio grew 57%. However, the company's legacy blockbuster Entresto, which treats heart failure, is now facing U.S. generic competition, with fourth-quarter sales dropping 45% year-over-year. Management has characterized 2026 as a transition year, guiding for low single-digit sales growth and a modest decline in core operating income. To bolster its pipeline, Novartis announced the $12 billion planned acquisition of Avidity Biosciences, targeting the neuromuscular disease space with antibody oligonucleotide conjugate (AOC) technology.
Trending AI Robots
For traders seeking a data-driven edge in a complex market, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed for real-world market conditions. With hundreds of AI trading bots available on the platform — each specializing in different tickers, timeframes, and trading styles — only the top performers earn placement in the Trending section. These bots employ diverse strategies ranging from swing trading to long-term trend following, with some recording annualized returns well into the double digits, Sharpe ratios above 1.5, and win rates exceeding 60%. Each bot's statistics, including trade history, maximum drawdown, and average trade duration, are fully transparent. Whether you are interested in pharmaceutical stocks like ABBV and NVS or a broader range of sectors, exploring the Trending AI Robots section can help identify algorithmically-driven opportunities aligned with current market conditions.
Head-to-Head Comparison
When comparing ABBV and NVS across key dimensions, several contrasts emerge. From a business model perspective, AbbVie derives a significant portion of its revenue from its immunology franchise, with Skyrizi and Rinvoq together annualizing at well over $25 billion. This concentration has been a strength, but it also means the company's fortunes are disproportionately tied to these two assets. Novartis, by contrast, has a more diversified portfolio across eight multi-billion-dollar brands spanning oncology, cardiovascular, neuroscience, and immunology, reducing single-product dependency.
On the growth trajectory, AbbVie currently holds the edge. With no significant loss-of-exclusivity (LOE) events expected for the remainder of the decade, the company projects high-single-digit compound annual growth through 2029. Novartis, meanwhile, is entering a patent cliff year in 2026 that will test its ability to sustain momentum as Entresto revenues decline. The company's 2025–2030 sales CAGR (compound annual growth rate) target of 5–6% reflects confidence but also acknowledges the near-term headwind.
Valuation tells a different story. AbbVie trades at a forward P/E (price-to-earnings) ratio of approximately 14.2, while Novartis carries a lower forward multiple, and discounted cash flow analysis suggests NVS may be closer to fair value or even undervalued relative to its free cash flow generation. AbbVie's dividend yield of roughly 3.1% exceeds Novartis's approximate 2.4%, although AbbVie's GAAP (Generally Accepted Accounting Principles) earnings-based payout ratio appears significantly elevated due to acquisition-related charges compressing reported net income. Novartis's dividend is covered more conservatively on a GAAP earnings basis.
Sector exposure and risk differ meaningfully. AbbVie has been diversifying into neuroscience and obesity through recent licensing deals, but the aesthetics segment remains a drag. Novartis has built leading positions in radioligand therapy and gene therapy — technological platforms that could provide durable competitive moats but also carry elevated clinical and regulatory risk. Both companies are active acquirers, and each has signaled continued appetite for bolt-on deals that can replenish early-stage pipelines.
Tickeron AI Verdict
Based on observable factors — including trend consistency, near-term growth momentum, and relative stability of the product portfolio — Tickeron's AI models would likely tilt in favor of ABBV in the current market environment. AbbVie's combination of accelerating immunology sales, a clean LOE runway through 2030, a rising dividend, and strong analyst sentiment creates a favorable alignment of signals that algorithmic models tend to reward. The company's recent stock outperformance relative to both the S&P 500 and the broader pharmaceutical sector further reinforces the trend. That said, NVS presents a compelling value case and a more diversified revenue base, which could become increasingly attractive as its 2026 patent expiry overhang clears and new pipeline assets mature. The probabilistic assessment is that AbbVie holds the advantage in the near-to-medium term, while Novartis may offer greater upside for investors willing to look through the current transitional period.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and NVS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileNVS’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 7 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.91% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 31, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | NVS | ABBV / NVS | |
| Capitalization | 458B | 295B | 155% |
| EBITDA | 16.9B | 22.4B | 75% |
| Gain YTD | 16.194 | 15.830 | 102% |
| P/E Ratio | 127.14 | 23.42 | 543% |
| Revenue | 62.8B | 56.6B | 111% |
| Total Cash | N/A | 6.98B | - |
| Total Debt | 72.9B | 47B | 155% |
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 6 | |
SMR RATING 1..100 | 1 | 28 | |
PRICE GROWTH RATING 1..100 | 7 | 46 | |
P/E GROWTH RATING 1..100 | 17 | 23 | |
SEASONALITY SCORE 1..100 | 28 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (66). This means that NVS’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as NVS (6). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (28). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (46). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.
ABBV's P/E Growth Rating (17) in the Pharmaceuticals Major industry is in the same range as NVS (23). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 39% | N/A |
| Stochastic ODDS (%) | 3 days ago 46% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 40% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 50% |
| Advances ODDS (%) | 3 days ago 59% | 10 days ago 52% |
| Declines ODDS (%) | 13 days ago 48% | 13 days ago 46% |
| BollingerBands ODDS (%) | 3 days ago 45% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 66% | 3 days ago 48% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BASAX | 20.94 | 0.10 | +0.48% |
| Brown Advisory Small-Cap Growth Adv | |||
| JCONX | 31.51 | N/A | N/A |
| Janus Henderson Contrarian I | |||
| GSCGX | 36.45 | -0.01 | -0.03% |
| Goldman Sachs Large Cap Equity A | |||
| QDISX | 20.80 | -0.02 | -0.10% |
| FI Instl Group Stock for Ret Plns | |||
| ALCZX | 22.29 | -0.13 | -0.58% |
| Alger International Opportunities Z | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.95% | ||
| BMY - ABBV | 52% Loosely correlated | +0.94% | ||
| NVS - ABBV | 50% Loosely correlated | -0.72% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.22% | ||
| MRK - ABBV | 45% Loosely correlated | +0.45% | ||
| JNJ - ABBV | 42% Loosely correlated | +1.59% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.